Clinical Trials Logo

Filter by:
  • Completed  
  • « Prev · Page [4]
NCT ID: NCT00384176 Completed - Colorectal Cancer Clinical Trials

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

HORIZON III
Start date: August 30, 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.

NCT ID: NCT00361335 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid arthritis (RA) despite concurrent MTX treatment. In addition, the safety of subcutaneous (SC) golimumab injections following transition from IV golimumab infusions will also be evaluated.

NCT ID: NCT00319254 Completed - Breast Neoplasms Clinical Trials

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.

NCT ID: NCT00134251 Completed - Parkinson's Disease Clinical Trials

Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations. Patients (outpatients) will be randomized to one of three different treatment arms.

NCT ID: NCT00078832 Completed - Breast Cancer Clinical Trials

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

IBIS II
Start date: September 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Anastrozole may be effective in preventing breast cancer. PURPOSE: This randomized clinical trial is studying how well anastrozole works in preventing breast cancer in postmenopausal women who are at increased risk for the disease.

NCT ID: NCT00072462 Completed - Breast Cancer Clinical Trials

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

IBIS-II DCIS
Start date: September 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ. PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.

NCT ID: NCT00038467 Completed - Breast Neoplasms Clinical Trials

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

IES
Start date: February 1998
Phase: Phase 3
Study type: Interventional

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

NCT ID: NCT00003026 Completed - Prostate Cancer Clinical Trials

Hormone Therapy in Treating Patients With Advanced Prostate Cancer

Start date: April 1997
Phase: Phase 3
Study type: Interventional

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase III trial to compare the effectiveness of long-term hormone therapy and triptorelin with no further treatment in treating patients who have advanced prostate cancer previously treated with radiation therapy and 6 months of androgen suppression.